Wisconsin Department of Employee Trust Funds Group Insurance Board

IBM Watson Health Update February 20, 2019



Watson Health

Agenda

- IBM Watson Health Engagement
- Key Performance Indicators (Dashboards)
- Key Trends Drilldown

IBM Watson Health & Wisconsin ETF DW/VBI Primary Objectives

These goals were recommended by Segal Consulting in 2015*

- Select a partner to ETF and the Board in analyzing data and trends to lead to data driven program design and development decisions.
- Support a Total Health Management model that includes driving engagement in wellness and disease management programming.
- Provide information to evaluate self-insurance and regionalization of the health insurance program.

^{*}http://etf.wi.gov/boards/agenda-items-2015/gib1117/item3ar.pdf

IBM Watson Health & Wisconsin ETF DW/VBI Primary Objectives

- Contain future cost increases and improve the health of participants by measuring and analyzing:
 - Medical and Pharmacy Quality Adherence
 - Health Management and Wellness Program Design
 - Benefit Design and Network Management
 - Provider and Facility Quality
 - Plan Performance and Contract Adherence
 - Financial Management

These objectives were presented by ETF in the DW/VBI Request for Proposal issued in 2016.

IBM Watson Health & Wisconsin ETF Project Status

- Solution components: Advantage Suite, Dynamic Health Insights & Benefit Modeler
- Initial contract period 03/1/2017 12/31/2018 with first renewal period of 01/01/2019 – 12/31/2020
- Began implementation in March 2017
 - Phase 1 completed May 2018 Database available
 - Phase 2 completed August 2018 Added data from three late data submitting entities and initial dashboards
- Data quality continually being evaluated and improved through collaborative work with the Data Submitting Entities (DSEs)


Key Performance Indicators

Financial

Previous Period: Sep 2016 - Aug 2017 (Incurred) Current Period: Sep 2017 - Aug 2018 (Incurred)







- Charge Submitted

Out of Pocket

Allowed Amount

Third Party Amount

Net Payment

Net Pay PMPM Dental



Net Pay PMPM Rx

Net Pay PMPM Med

Net Pay PMPM

Financial

Previous Period: Sep 2016 - Aug 2017 (Incurred) Current Period: Sep 2017 - Aug 2018 (Incurred)



Cost Per Member

	Previous	Current	% Change Norm		% Difference from Norm		
Allow Amt PMPY Med and Rx	\$7,494	\$7,980	6.5%	A	\$6,526	22.3%	A
Allow Amt Per Visit Office Med	\$204	\$212	4.1%	\blacktriangle			
Allow Amt Per Adm Acute	\$19,381	\$20,564	6.1%	\blacktriangle	\$28,673	-28.3%	\blacksquare
Allow Amt Per Visit ER	\$1,466	\$1,559	6.3%	\blacktriangle	\$1,873	-16.8%	\blacksquare
Allow Amt Per Script Rx	\$118	\$123	4.7%	\blacktriangle	\$126	-2.1%	\blacksquare
Visits Per 1000 Office Med	6,956	6,941	-0.2%		5,839	18.9%	
Admits Per 1000 Acute	70	70	-0.3%		57	23.9%	
Visits Per 1000 ER	269	270	0.3%		213	26.9%	
Scripts Per 1000 Rx	15,990	15,763	-1.4%				

Cost Drivers

Allowed Amount PMPY increased \$485 in the current period. The factors driving this change include:





Clinical

Previous Period: Sep 2016 - Aug 2017 (Incurred) Current Period: Sep 2017 - Aug 2018 (Incurred)




10 Most Expensive Clinical Conditions





High Cost Claimants (HCC) Trends



Top 10 Conditions for *Consistent HCC

	Allow Amt Med	Patients	**Allow Amt Per Patient Med
Chemotherapy Encounters	\$15,632,612	302	\$51,764
Renal Function Failure	\$9,155,344	332	\$27,576
Signs/Symptoms/Oth Cond, NEC	\$8,502,039	1,940	\$4,382
Condition Rel to Tx - Med/Surg	\$5,740,608	394	\$14,570
Infections, NEC	\$5,300,725	503	\$10,538
Respiratory Disord, NEC	\$5,121,880	991	\$5,168
Crohns Disease	\$4,553,423	210	\$21,683
Cancer - Leukemia	\$4,185,969	152	\$27,539
Multiple Sclerosis	\$4,057,306	266	\$15,253
Gastroint Disord, NEC	\$3,761,565	805	\$4,673

HCC: defined as member with allowed amount >= \$50K.

*Consistent HCC: in addition, member must meet the HCC requirement for each of the last 2 Incurred Rolling years.

^{**}Only costs associated with this condition in the current period, patients may have multiple conditions.


Clinical

*Current Period: Sep 2017 - Aug 2018 (Incurred)


**DCG Period: Jan 2017 - Dec 2017



% of Members by Risk Band



Risk Band Profiles



^{*}Demographic and financial metrics are for the current period


^{**}See glossary for details on DCG Methodology

Financial

Previous Period: Sep 2016 - Aug 2017 (Incurred) Current Period: Sep 2017 - Aug 2018 (Incurred)



Enrollment and Allowed Amount PMPY by Plan Group



Size of the bubbles represent current enrollment in each plan group X-axis: % Change Allowed Amount PMPY Current vs Previous for each plan group

Eligibility


Previous Period: Sep 2016 - Aug 2017 (Incurred) Current Period: Sep 2017 - Aug 2018 (Incurred)



	Enrollment			Average Age				
	Previous	ous Current % Change		revious Current % Cha		Previous	Current	% Change
Employees	120,409	119,000	-1.2%	51.1	51.0	-0.1%		
Members	267,300	262,017	-2.0%	39.3	39.3	0.1%		
Family Size Avg	2.2	2.2	-0.9%					

Membership and Net Pay PMPM by Gender

	Previous	Current	% Change
Female	138,048	135,627	-1.8%
Male	129,252	126,469	-2.2%




*Membership and Net Pay PMPM


	Previous	Current	% Change
Employee/Self	120,372	118,440	-1.6%
Spouse	63,235	61,591	-2.6%
Child/Other Dependent	83,690	81,986	-2.0%

by Employee Relationship

* Membership and Net Pay PMPM by Employee Status

	Previous	Current	% Change	
Active	223,322	218,031	-2.4%	
Early Retiree	11,743	11,323	-3.6%	
Medicare Retiree	37,002	37,085	0.2%	
Other	1.229	1.600	30.2%	






^{*}Membership counts may not be unique since there may be transitions between the listed categories during the reported period

Key Trends Drilldown


Previous Rolling Year: Sep 2016 – Aug 2017 Current Rolling Year: Sep 2017 – Aug 2018




Preventive: preventive visits, immunizations, blood pressure tests, screenings (e.g., mammograms, colonoscopies), lipid tests, etc. Office: office visits not in preventive Lab: lab services not in preventive Diagnostic: radiology and other diagnostic services (e.g., EKG, echocardiogram, spirometry) not in preventive PT/OT/ST/CT: physical therapy, occupational therapy, speech therapy, and chiropractic therapy Surgery: surgical services not in preventive ER: emergency room Treatments: dialysis, specialty drugs, OP pharmacy, and injections not in preventive Other: DME, medical supplies/devices, home health, minor procedures (e.g., skin lesion biopsy), etc.

- Increased utilization of laboratory services and non-preventive office (primarily physician non-specialty) accounted for about half of the overall 7% outpatient utilization trend
- Regular and high cost claimants contribute approximately equally to the 11% trend in laboratory services - high cost claimants do not use these services disproportionately

Previous Rolling Year: Sep 2016 – Aug 2017 Current Rolling Year: Sep 2017 – Aug 2018





- The 6% increase in inpatient price was largely accounted for by surgical admissions
 - The 9% jump in surgical admission price is mostly driven by increases in severity (changes in case mix accounted for eight percentage points of the 9% surgical price increase)
 - Surgeries related to musculoskeletal conditions is the highest contributor to surgical price trend,
 accounting for half of the increase
- The overall trend of inpatient use is 1% year over year

Comparison To Other Large Employers

Previous Rolling Year: Sep 2016 – Aug 2017 Current Rolling Year: Sep 2017 – Aug 2018

	Above Norm Below Norm	Cost, Use, and Price Rates*		Trends**		
	♦ Similar to Norm (within 2%)	WIETF	Norm	Comparison	WIETF	Norm
	Medical: Allowed Amounts per Member	\$5,343	\$4,855	•	6%	4%
	Medical: Net Payments per Member	\$4,932	\$3,976	•	6%	4%
<u></u>	Inpatient: Admits per 1,000 Members	53	55	•	-1%	-2%
Medical	Inpatient: Average Length of Stay	3.5	4.1	•	5%	-2%
Š	Inpatient: Allowed Amounts per Admit	\$22,306	\$24,052	•	6%	3%
	Outpatient: Services per Member	23.8	27.5	•	5%	1%
	Outpatient: Allowed Amounts per Service	\$170	\$126	•	2%	3%
	Rx: Allowed Amounts per Member	\$1,099	\$1,346	•	1%	4%
%	Rx: Net Payments per Member	\$1,001	\$1,187	•	2%	4%
	Rx: Allowed Amount per Days Supply	\$2.81	\$3.68	•	0%	3%
	Rx: Days Supply per Member	392	366	•	1%	1%

¹ MarketScan (MSN) Norms were adjusted where appropriate (age/gender, geographic, severity) to the WI ETF population

WI ETF had higher overall medical rate than the Norm, this is also trending higher

- Utilization and costs are comparable or better than the Norm but the overall cost difference is driven by the cost per service
- Prescription drug costs are lower and trending lower than the Norm


^{*} Rates for WI ETF are CRY and for Norm are 2016 MSN U.S. Total norms trended to CRY utilizing 4Q17 and 2Q18 Employer Semi-Annual Norm trends

^{**}Trends represent PRY to CRY for WI ETF and 2Q18 Employer Semi-Annual Norm Trends

Benefit Utilization

% of Members Utilizing Medical or Rx Benefit by Relationship





- **87%** of members used the medical benefit
- **70%** of members used the prescription drug (Rx) benefit
- 90% of members used either the medical or Rx benefit
- Overall, 10% of members did not use the medical or prescription drug benefit in the current rolling year
 - Males had lower utilization than females
- Males age 18-34 had the lowest use of benefits, with 28% of members not incurring a claim

Preventive Care Utilization





Spouses with a Preventive Care Service




Children with a Preventive Care Service



52% of females had a preventive care service


40% of males had a preventive care service

% of Members with a Preventive Service




- Overall, 54% of members did not have a preventive care service in the current rolling year
- Males age 18-34 had the lowest use of preventive care with 81% of members not incurring a service; 68% of males age 35-54 did not incur a preventive service

Member Engagement







Glossary of Terms

Time Periods

- CRY: Current Rolling Year
- DCG Periods
 - Related to Diagnostic Cost Group methodology and risk adjustment
 - Typically aligned with Jan Dec plan year
- Incurred: the date a service was rendered
- Paid: the date that the claim for a service was paid
- PRY: Previous Rolling Year

Clinical

- Clinical Conditions: IBM description for a clinical condition based on valid ICD principal diagnosis
- IP: inpatient service, related to an admission
- OP: outpatient services
- Rx: prescription drugs

Eligibility

- Employees: subscriber/self
- Family Size: average number of covered members per family
- Member Age: average age of covered employees/members
- Members: subscribers and dependents

Financial

- Allowed Amount: the total amount paid to the provider by all parties the underlying medical cost that drives spending
- Net Payment: the amount paid by the plan sponsor (WI ETF)
 - Net Payment = Allowed Amount (OOP + Third Party Payment)
- OOP: Out Of Pocket, cost to member
- Rates:
 - PMPM: Per Member Per Month
 - PMPY: Per Member Per Year
- Third Party Payment: e.g. Medicare, Medicaid, and other insurance

Other

- DCG: Diagnostic Cost Group (DCG) classifications are the foundation of a family of risk-adjusted payment and analysis methodologies
- Risk Scores and Categories
 - Are the predicted patient risk based on (i) Diagnosis codes (ICD 9/10) and (ii) Demographics
 - Concurrent / prospective: current and predicted risk scores
 - NonRescaled: DCG model population reference / average = 100
 - Rescaled: WI ETF population reference / average = 100
 - Risk Bands: groupings of risk scores based on IBM MarketScan®

Legal Disclaimer

© IBM Corporation 2019. All Rights Reserved.

The information contained in this publication is provided for informational purposes only. While efforts were made to verify the completeness and accuracy of the information contained in this publication, it is provided AS IS without warranty of any kind, express or implied. In addition, this information is based on IBM's current product plans and strategy, which are subject to change by IBM without notice. IBM shall not be responsible for any damages arising out of the use of, or otherwise related to, this publication or any other materials. Nothing contained in this publication is intended to, nor shall have the effect of, creating any warranties or representations from IBM or its suppliers or licensors, or altering the terms and conditions of the applicable license agreement governing the use of IBM software.

References in this presentation to IBM products, programs, or services do not imply that they will be available in all countries in which IBM operates. Product release dates and/or capabilities referenced in this presentation may change at any time at IBM's sole discretion based on market opportunities or other factors, and are not intended to be a commitment to future product or feature availability in any way. Nothing contained in these materials is intended to, nor shall have the effect of, stating or implying that any activities undertaken by you will result in any specific sales, revenue growth or other results.

Performance is based on measurements and projections using standard IBM benchmarks in a controlled environment. The actual throughput or performance that any user will experience will vary depending upon many factors, including considerations such as the amount of multiprogramming in the user's job stream, the I/O configuration, the storage configuration, and the workload processed. Therefore, no assurance can be given that an individual user will achieve results similar to those stated here.

All customer examples described are presented as illustrations of how those customers have used IBM products and the results they may have achieved. Actual environmental costs and performance characteristics may vary by customer.

IBM, the IBM logo, ibm.com, and Watson Health are trademarks of International Business Machines Corp., registered in many jurisdictions worldwide. Other product and service names might be trademarks of IBM or other companies. A current list of IBM trademarks is available on the Web at "Copyright and trademark information" at ibm.com/legal/copytrade.